Preclinical models have shown that the NLRP3 components are expressed in cardiomyocytes and cardiac fibroblasts, and recent studies have identified the NLRP3 inflammasome as a critical nodal point in the pathogenesis of cardiomyopathies and hypoxic injury, which may create an opportunity for the development of new therapeutic agents [16]. The gene discussed is NLRP3; the disease is cardiomyopathy.